Phase 1 study of VX-152, a next-generation corrector alone and in combination with VX-661/ivacaftor in healthy volunteers

Trial Profile

Phase 1 study of VX-152, a next-generation corrector alone and in combination with VX-661/ivacaftor in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs VX 152 (Primary) ; Ivacaftor/tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by Vertex media release.
    • 30 Oct 2015 New trial record
    • 09 Oct 2015 According to a Vertex Pharmaceutical media release, this trial will begin in November 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top